Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00043537 · ClinicalTrials.gov registry record · Phase 3
Treatment of Childhood Social Phobia
A Phase 3 study of Social Phobia, sponsored by University of Central Florida.
- Completed
- Registry status
- Phase 3
- Development phase
- 139
- Enrollment target
- 1
- Study location
NCT00043537: Completed Phase 3 study of Social Phobia, sponsored by University of Central Florida.
NCT00043537 is a Phase 3 study of Social Phobia that has completed, run by University of Central Florida. The registered enrollment target is 139 participants, roughly in line with the 133-participant average among 8 other Social Phobia trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00043537, a Phase 3 study of Social Phobia, has completed, sponsored by University of Central Florida.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 139 participants
- Enrollment target
- 1
- Study location
Study Summary
This 4-year study will compare the long-term effectiveness of behavioral treatment, fluoxetine (Prozac®), and placebo for treatment of social phobia in children and adolescents.
Conditions Studied
Interventions
- DRUG Fluoxetine
- DRUG Pill Placebo
- BEHAVIORAL Social Effectiveness Therapy for Children (SET-C)
Study Locations (1)
Maryland
- Maryland Center for Anxiety Disorders - University of Maryland, College Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2001-04 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
What the finished NCT00043537 record still lists
NCT00043537 is an interventional study that assigns participants to a tested intervention. The registered 139 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 8 other Social Phobia trials with a reported enrollment target.
The record links to 1 condition, with Social Phobia appearing as the primary indexed condition, and to 3 interventions - of which Fluoxetine is the first listed.
NCT00043537 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00043537 about?
NCT00043537 is a clinical study titled "Treatment of Childhood Social Phobia". This 4-year study will compare the long-term effectiveness of behavioral treatment, fluoxetine (Prozac®), and placebo for treatment of social phobia in children and adolescents.
What is the current status of trial NCT00043537?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 139 participants. The study started on 2001-04. Estimated completion is 2006-09.
What conditions does trial NCT00043537 study?
This clinical trial studies the following conditions: Social Phobia.
What interventions are being tested in trial NCT00043537?
The interventions under investigation include: Fluoxetine (DRUG), Pill Placebo (DRUG), Social Effectiveness Therapy for Children (SET-C) (BEHAVIORAL).
Who is sponsoring clinical trial NCT00043537?
This trial is sponsored by University of Central Florida, which has 91 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00043537 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Social Phobia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00043537's enrollment target sits among peer trials
139 5th of 8 higher than 4 of 8 other Social Phobia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Social Phobia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mindful Self-Compassion for Anxiety Disorders and Depression
RECRUITING · NA
-
Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals
ACTIVE NOT RECRUITING · NA
-
Psychotherapy for Anxiety in Children With Autism Spectrum Disorder
COMPLETED · NA
-
Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder
COMPLETED · Phase 2
-
Safety and Efficacy Study of AV608 in Subjects With Social Anxiety Disorder
COMPLETED · Phase 2
-
Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05645380 · 139 participants · Phase 2
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
- NCT06239272 · 139 participants · Phase 1
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- NCT06252220 · 139 participants · Phase 1
First in Human Study in Subjects With Obesity, But Otherwise Healthy
- NCT06537128 · 139 participants · NA
Internet-delivered Cognitive-Behavioral Therapy for Adolescents With Autism and Anxiety
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia